Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclic RGD peptides are a class of synthetic cyclic peptides containing the arginine-glycine-aspartic acid (RGD) tripeptide motif. They are designed to mimic the cell adhesion domain of extracellular matrix proteins like fibronectin and vitronectin, allowing them to bind with high affinity and selectivity to integrins, particularly integrin alpha-V/beta-3 (αvβ3) and integrin alpha-V/beta-5 (αvβ5). These integrins are highly overexpressed on angiogenic endothelial cells and various tumor cells, making cyclic RGD peptides valuable tools for targeted drug delivery (such as in liposomes or nanoparticles) and as molecular imaging probes (when radiolabeled) for cancer detection and monitoring.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclic RGD peptide.